Modality
Vaccine
MOA
GLP-1/GIP
Target
C5
Pathway
Amyloid
SMATTR Amyloidosis
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
Apr 2018
→ Jun 2027
Phase 1Current
NCT06797518
304 pts·SMA
2018-04→2027-06·Terminated
304 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-06-071.2y awayPh2 Data· SMA
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1/2
Termina…
Catalysts
Ph2 Data
2027-06-07 · 1.2y away
SMA
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06797518 | Phase 1/2 | SMA | Terminated | 304 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Elratapinarof | Halozyme | Phase 2 | C5 |